Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy, Haduviotm (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary ...

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE ...